Since BRAF inhibitors may induce increased PD-L1 expression in tumor cells and help restore the immune-stimulating microenvironment of BRAF-mutant melanoma (50), the combination of BRAF inhibitors and ICIs may provide a stronger antitumor effect. The gene discussed is CD274; the disease is neoplasm.